Lavipharm Valuation
| LAVI Stock | EUR 0.71 0.01 1.39% |
Lavipharm is overvalued. Lavipharm SA secures a last-minute Real Value of €0.62 per share. The latest price of the firm is €0.71. Our model forecasts the value of Lavipharm SA from analyzing the firm fundamentals such as Operating Margin of 0.08 %, shares outstanding of 18.29 M, and Return On Asset of 0.0403 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Lavipharm's price fluctuation is dangerous at this time. Calculation of the real value of Lavipharm SA is based on 3 months time horizon. Increasing Lavipharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Lavipharm's intrinsic value may or may not be the same as its current market price of 0.71, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.71 | Real 0.62 | Hype 0.71 | Naive 0.68 |
The intrinsic value of Lavipharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lavipharm's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lavipharm SA helps investors to forecast how Lavipharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lavipharm more accurately as focusing exclusively on Lavipharm's fundamentals will not take into account other important factors: Lavipharm Total Value Analysis
Lavipharm SA is now anticipated to have takeover price of 59.98 M with market capitalization of 8.56 M, debt of 40.54 M, and cash on hands of 1.85 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Lavipharm fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
59.98 M | 8.56 M | 40.54 M | 1.85 M |
Lavipharm Investor Information
About 67.0% of the company outstanding shares are owned by corporate insiders. The company last dividend was issued on the 20th of August 2007. Lavipharm SA had 1:3 split on the 1st of August 2022. Based on the analysis of Lavipharm's profitability, liquidity, and operating efficiency, Lavipharm SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Lavipharm Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lavipharm has an asset utilization ratio of 50.45 percent. This implies that the Company is making €0.5 for each dollar of assets. An increasing asset utilization means that Lavipharm SA is more efficient with each dollar of assets it utilizes for everyday operations.Lavipharm Ownership Allocation
Lavipharm SA maintains a total of 18.29 Million outstanding shares. Lavipharm SA secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 67.47 % of Lavipharm SA outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lavipharm Profitability Analysis
The company reported the revenue of 41.37 M. Net Income was 1.72 M with profit before overhead, payroll, taxes, and interest of 15.89 M.About Lavipharm Valuation
The stock valuation mechanism determines Lavipharm's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Lavipharm SA based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lavipharm. We calculate exposure to Lavipharm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lavipharm's related companies.Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange.
8 Steps to conduct Lavipharm's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Lavipharm's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Lavipharm's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Lavipharm's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Lavipharm's revenue streams: Identify Lavipharm's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Lavipharm's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Lavipharm's growth potential: Evaluate Lavipharm's management, business model, and growth potential.
- Determine Lavipharm's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Lavipharm's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.